NIH Plans Closed Sessions for Brain and Eye Grant Reviews
Published Date: 5/7/2025
Notice
Summary
The NIH’s Center for Scientific Review is holding several closed virtual meetings in June 2025 to review and decide on important brain and eye disease research grant applications. These meetings keep sensitive info private to protect ideas and personal details. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Confidentiality protects applicants' ideas
The meetings are closed under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, patentable material, and personal information. This keeps applicants' sensitive research ideas and personal details private during grant review.
NIH grant reviews held June 2025
If you applied for NIH research grants in the listed study sections, your applications will be reviewed on these closed virtual meeting dates: June 5-6, 2025; June 6, 2025; and June 9-10, 2025. These reviews are the meetings that evaluate and decide on grant applications.
Virtual format — no public attendance or extra costs
All listed meetings are virtual and closed to the public, and they do not involve public attendance or extra costs. You will not be able to attend these meetings in person and there is no public travel required for the listed review dates.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-07943, Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Coding
Hey Medicare providers and healthcare pros! CMS is kicking off 2025 with a public meeting to chat about updates to the HCPCS codes, which help decide how services and items get paid. This is your chance to learn about possible changes that could affect payments and benefits, so don’t miss out on registering and having your say!
Next: 2025-07945, Erythritol From People's Republic of China: Postponement of Preliminary Determination in the Less-Than-Fair-Value Investigation
The U.S. is taking more time to decide if erythritol from China is being sold unfairly cheap. This delay helps make sure the investigation is super accurate and fair. Companies importing or selling erythritol should expect the decision to come later than planned, which could affect duties and prices.